We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+7.35%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$438M
AUM Growth
+$79M
Cap. Flow
+$247M
Cap. Flow %
56.34%
Top 10 Hldgs %
55.67%
Holding
153
New
56
Increased
27
Reduced
23
Closed
42

Sector Composition

Rank Sector Weight
1 Healthcare 75.26%
2 Miscellaneous 13.69%
3 Consumer Discretionary 3%
4 Technology 2.66%
5 Industrials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CSX icon
26
CSX Corp
CSX
$89.1B
$3.38M 0.77%
350,475
+130,500
+59% +$1.21M
TEVA icon
27
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$3.25M 0.74%
61,600
-88,400
-59% -$4.09M
GOOG icon
28
Alphabet (Google) Class C
GOOG
$4.19T
$3.19M 0.73%
+114,989
New +$3.35M
PCP
29
DELISTED
PRECISION CASTPARTS CORP
PCP
$3.17M 0.72%
12,520
+2,000
+19% +$518K
XLI icon
30
State Street Industrial Select Sector SPDR ETF
XLI
$30.7B
$2.86M 0.65%
54,623
-40,000
-42% -$2.05M
CLVS
31
DELISTED
Clovis Oncology, Inc.
CLVS
$2.77M 0.63%
40,000
-5,000
-11% -$367K
CVS icon
32
CVS Health
CVS
$116B
$2.68M 0.61%
+35,795
New +$2.53M
BKNG icon
33
Booking.com
BKNG
$128B
$2.67M 0.61%
56,050
+6,675
+14% +$329K
TEVA icon
34
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$2.53M 0.58%
3,000
-97,000
-97% -$4.48M
TBRA
35
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.5M 0.57%
+22,222
New +$1.56M
RDHL
36
Redhill Biopharma
RDHL
$3.65M
$2.43M 0.55%
+1,715
New +$23M
NGNE icon
37
Neurogene
NGNE
$651M
$2.42M 0.55%
+9,500
New +$2.44M
AERI
38
DELISTED
Aerie Pharmaceuticals
AERI
$2.38M 0.54%
112,500
+2,500
+2% +$50.5K
NPSP
39
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$2.33M 0.53%
78,000
-50,000
-39% -$1.72M
LVS icon
40
Las Vegas Sands
LVS
$26.6B
$2.25M 0.51%
27,847
+3,170
+13% +$255K
CASC
41
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.21M 0.5%
123,056
-1,667
-1% -$27.4K
IRD
42
Opus Genetics
IRD
$438M
$2.17M 0.49%
4,180
+1,055
+34% +$571K
PRTA icon
43
Prothena Corp
PRTA
$434M
$2.11M 0.48%
55,000
+5,000
+10% +$161K
NVMI
44
Nova
NVMI
$11B
$2.03M 0.46%
+181,184
New +$2M
SILC icon
45
Silicom
SILC
$269M
$1.99M 0.45%
32,088
-5,733
-15% -$354K
TRVN
46
DELISTED
Trevena, Inc.
TRVN
$1.97M 0.45%
+400
New +$1.96M
EOCN
47
Eocene Ltd. Ordinary Shares
EOCN
$3.82M
$1.95M 0.45%
+118
New +$2.21M
SCHW
48
Charles Schwab
SCHW
$181B
$1.89M 0.43%
69,200
-28,727
-29% -$751K
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.82M 0.42%
+100,000
New +$1.81M
CHKP icon
50
Check Point Software Technologies
CHKP
$13.9B
$1.79M 0.41%
26,513
-28,840
-52% -$1.91M

Similar funds

Sphera Funds Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sphera Funds Management held 153 positions worth $438M, up 22% from $359M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sphera Funds Management deployed $247M of net new capital in Q1 2014, opening 56 new positions and adding to 27 existing holdings. Its largest new stake was Summit Financial Group, Inc.: 10,921,656 shares worth $1.75M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 45% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $4.09M trimmed.

  • Sphera Funds Management's largest Q1 2014 buy was Summit Financial Group, Inc.: 10,921,656 shares worth $1.75M.
  • Sphera Funds Management added most to Novartis in Q1 2014, an estimated $41.1M increase.
  • Sphera Funds Management's biggest Q1 2014 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $4.09M.
  • Sphera Funds Management fully exited Shire pic in Q1 2014, selling an estimated $9.18M.
  • Sphera Funds Management's ten largest holdings make up 56% of its $438M portfolio in Q1 2014.
  • Sphera Funds Management opened 56 new positions and closed 42 in Q1 2014.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $438M.

Based on Sphera Funds Management's 13F filing for Q1 2014, filed 14 May 2014.